Dr. Reddy’s Laboratories (Pharma Sector)

Dr. Reddy’s ADR gained a Relative Strength Rating of 81 (up from 78), with consistent EPS growth and strong technical indicators. Rationale: The pharmaceutical sector benefits from global generic drug demand and increased R&D efficiency. Dr. Reddy’s is expanding in global markets and innovating in complex generics, making it a strong long-term candidate with technical strength and business growth alignment.